Lyell Immunopharma, Inc. (LYEL) vs Sionna Therapeutics, Inc. (SION)

Lyell Immunopharma, Inc. and Sionna Therapeutics, Inc. are both Biotechnology companies. Lyell Immunopharma, Inc. and Sionna Therapeutics, Inc. are of similar size ($248.0M and $241.9M). Sionna Therapeutics, Inc. has the higher net margin (0.00% vs −920,285.2%) and the higher return on invested capital (−125.0% vs −539.5%). Across the 12 metrics below, Sionna Therapeutics, Inc. leads on 11 and Lyell Immunopharma, Inc. on 1.

Valuation

Metric LYEL SION Biotechnology median
P/E n/m n/m 7.88
P/S 8,523.53 n/m 11.47
P/B 0.98 0.89 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 964.20 n/m 10.73
Earnings yield (130.25%) (41.68%) (28.84%)
Free cash flow yield (75.99%) (32.31%) (23.03%)

Profitability

Metric LYEL SION Biotechnology median
Gross margin 100.00% — 65.16%
Operating margin (949,981.48%) 0.00% 0.00%
Net margin (920,285.19%) 0.00% 0.00%
Free cash flow margin (647,681.48%) 0.00% 0.00%
Return on equity (93.28%) (32.34%) (57.72%)
Return on assets (71.34%) (30.66%) (49.22%)
Return on invested capital (539.53%) (125.00%) 0.00%

Growth

Metric LYEL SION Biotechnology median
Revenue growth (TTM) (55.00%) — 5.64%
EPS growth (last fiscal year) 38.70% 88.24% —
Revenue growth, 5-year CAGR (65.85%) — 8.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric LYEL SION Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 5.36 20.05 4.73
Net debt to EBITDA 0.94 2.58 0.96

Dividend

Metric LYEL SION Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric LYEL SION Biotechnology median
Market cap 247.99m 241.89m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack